Merck & Co., Inc. vs Motorola Solutions Inc — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Motorola Solutions Inc trades at $405.33 (market cap $68.13B). The key difference: Merck & Co., Inc. is far larger — about 4.5× Motorola Solutions Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | MSI | |
|---|---|---|
Market Cap | $307.25B | $68.13B |
Sector | Health | Technology |
52-Week High | $129.52 | $490.30 |
52-Week Low | $77.60 | $363.83 |
Enterprise Value | $350.66B | $76.83B |
Dividend Yield | 2.73% | 1.18% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Motorola Solutions (MSI) trades at $406.28, down 1.7% on the day, with a bearish technical signal. The company reported strong earnings beats in recent quarters and maintains robust profitability with a 17.61% net margin and 99.88% ROE. Recent developments include the $1.5 billion acquisition of D-Fend Solutions and expansion of AI capabilities for emergency response systems, signaling strategic growth in public safety technology.
The outlook remains positive with a consensus price target of $512.33, implying 26% upside, supported by 71% analyst buy ratings. Risks include elevated valuation multiples (P/E 33.1) and significant investing cash outflows for acquisitions. The stock's near-term performance will hinge on execution of growth initiatives and Q2 2026 earnings relative to the $3.86 EPS estimate.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →